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Background: Compared with younger patients, older adults with acute myeloid leukemia (AML) generally have
poorer survival outcomes and less benefit from clinical trials. A recent phase 3 trial demonstrated a trend toward
improved overall survival (OS) with decitabine, a hypomethylating agent, compared with treatment choice of either
cytarabine or supportive care (7.7 months, 95% CI: 6.2–9.2 vs 5.0 months, 95% CI: 4.3–6.3, respectively) in older
adults with newly diagnosed AML. The current analyses investigated prognostic factors for outcomes in this trial
and examined OS and responses in prespecified subgroups.
Methods: A multivariate Cox proportional hazards model was used to investigate effects of demographic and
baseline characteristics, including age, sex, cytogenetic risk, AML type, ECOG Performance Status, geographic region,
bone marrow blasts, platelets, and white blood cells on OS, based on mature data. Similar analyses were conducted
with a logistic regression model to predict response rates. Prespecified subgroup analyses were performed for OS
and response rates, also using mature data.
Results: Patient characteristics that appeared to negatively influence OS included more advanced age (hazard ratio
[HR] 1.560 for ≥75 vs <70 years; p = 0.0010), poorer performance status at baseline (HR 0.771 for 0 or 1 vs 2; p = 0.0321),
poor cytogenetics (HR 0.699 for intermediate vs poor; p = 0.0010), higher bone marrow blast counts (HR 1.355 for >50%
vs ≤50%; p = 0.0045), low baseline platelet counts (HR 0.775 for each additional 100 × 109/L; p = 0.0015), and high white
blood cell counts (HR 1.256 for each additional 25 × 109/L; p = 0.0151). Regarding geographic regions, patients from
Western Europe had the longest median OS. Response rates favored decitabine for all subgroups investigated,
including patients ≥75 years (odds ratio 5.94, p = 0.0006).
Conclusion: Response to decitabine in AML is associated with known prognostic factors related to both patient
demographics and disease characteristics.
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The European LeukemiaNet [1], European Society of
Medical Oncology [2], and National Comprehensive
Cancer Network (US) [3] recently indicated that manage-
ment of patients aged ≥60 years with acute myeloid
leukemia (AML) should be guided by performance status
and presence of comorbidities. Until recently, treat-
ment approaches had proven difficult in older pa-
tients. However, international treatment guidelines for
AML now include low-intensity cytarabine, 5-azacyti-
dine, and decitabine as therapeutic options [1,3].
Decitabine, a hypomethylating agent, was approved
by the European Medicines Agency in late 2012 for
treatment of patients aged ≥65 years with newly diag-
nosed de novo or secondary AML [4]. Decitabine ap-
pears to have direct cytotoxic effects and is believed
to affect cellular differentiation and apoptosis. In the
US, it is indicated for treatment of previously treated
and untreated de novo and secondary myelodysplastic
syndrome (MDS) of all French-American-British sub-
types and intermediate-1, intermediate-2, and high-risk
International Prognostic Scoring System groups [5]. In pa-
tients with MDS [6], chronic myelomonocytic leukemia
[6], or AML, intravenous (IV) decitabine 20 mg/m2 ad-
ministered daily for 5 consecutive days every 4 weeks was
well tolerated [7].
A recently reported phase 3 trial in older patients
(≥65 years) with newly diagnosed AML and poor- or
intermediate-risk cytogenetics compared the efficacy
and safety of decitabine with patient’s treatment
choice (TC), upon physician’s advice, of supportive
care (SC) or cytarabine [8]. The study had a planned
clinical cutoff date of October 28, 2009; 396 deaths
had occurred. The primary efficacy analysis (October
2009) showed a nonsignificant trend toward increased me-
dian overall survival (OS) with decitabine (7.7 months;
95% confidence interval [CI]: 6.2–9.2 months) versus
TC (5.0 months; 95% CI: 4.3–6.3 months), with an
estimated hazard ratio (HR) of 0.85 (p = 0.108). In a
post hoc analysis using mature data (clinical cutoff
October 29, 2010) [8], 446 deaths had occurred. Me-
dian OS was the same as that in the 2009 analysis,
but with improved HR (0.82; 95% CI: 0.68–0.99; no-
minal p = 0.037) with decitabine. At the 2009 cutoff,
significantly improved remission rates were observed
with decitabine versus TC (complete response [CR] or
CR with incomplete platelet recovery [CRp], 17.8% vs
7.8%, respectively; p = 0.001), and decitabine was well
tolerated.
Using mature (2010) data from the phase 3 trial [8],
this multivariate analysis aimed to identify potential pre-
dictors of survival and response in this older population
with AML. Prespecified analyses of response and sur-
vival by subgroups are also reported.Methods
Patients and study design
Patients aged ≥65 years with newly diagnosed, histologi-
cally confirmed de novo or secondary AML (≥20% blasts),
poor- or intermediate-risk cytogenetics (Southwest Oncol-
ogy Group categorization [9]), and Eastern Cooperative
Oncology Group (ECOG) Performance Status (PS) of 0–2
were eligible. Excluded patients had t(15;17), t(8;21), or
inv(16) karyotype abnormalities. Complete protocol details
were previously reported [8].
This study, conducted in 15 countries, was approved by
institutional review boards or independent ethics commit-
tees and conducted in accordance with the Declaration of
Helsinki. All patients provided written, informed consent.
Patients in this randomized, open-label, phase 3 trial in-
dicated, with physician’s advice, their preferred TC of SC
or once-daily cytarabine 20 mg/m2 subcutaneously for 10
consecutive days every 4 weeks. Patients were randomized
1:1 to receive decitabine or TC, stratified by age, cytogen-
etic risk, and ECOG PS. Once-daily decitabine 20 mg/m2
was administered as a 1-hour IV infusion for 5 consecu-
tive days every 4 weeks. Treatment continued until relapse
or progressive disease (PD), death, unacceptable toxicity,
lack of clinical benefit, intercurrent illness preventing
treatment, or patient/physician request.
The primary objective was to compare OS (from ran-
domization to death) in patients receiving decitabine ver-
sus TC. Secondary objectives were to compare response
rates, including CR and CRp, based on bone marrow biop-
sies and aspirates. Patients were followed monthly for 2
years post-randomization, then every 2 months for 3 years
for OS and PD until death or loss to follow-up.
Statistical analysis
The primary OS analysis was based on the 2009 clinical
cutoff date [8]. To provide additional data, a post hoc
analysis evaluated mature 2010 survival data [8]. Mature
data were utilized for this multivariate analysis. At the
2010 clinical cutoff, >90% of events were recorded.
A multivariate Cox proportional hazards model was
used to investigate the effects of the following baseline
characteristics on OS: gender, age (<70, 70 to <75, and
≥75 years), baseline cytogenetic risk (intermediate vs
poor), AML type (de novo vs secondary), baseline ECOG
PS (0/1 vs 2), region (North America/Australia, Western
Europe, Eastern Europe, or Asia), baseline bone marrow
blasts (>50% vs ≤50%), baseline platelet counts (at each
unit of 100 ×109/L), and baseline white blood cell (WBC)
counts (at each unit of 25 ×109/L). These potential prog-
nostic factors were evaluated all at once and p values de-
termined without adjustment for multiple testing.
For probability of achieving CR or CRp, a logistic re-
gression model was used to investigate effects of the
same demographic and baseline characteristics. Again,
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determined without adjustment for multiple testing.
Prespecified subgroup analyses were additionally per-
formed based on mature data to compare OS between
decitabine and TC using the Cox regression model
stratified by age, cytogenetic risk, and ECOG PS (same
model used for the study’s primary OS analysis) [8]. Sub-
groups included those with baseline bone marrow blasts
≥20% and ≤30% versus >30%; de novo versus secondary
AML; intermediate-risk versus poor-risk cytogenetics;
ages <70, 70–74, and ≥75 years; and ECOG PS of 0–1
versus 2. Regional subgroups were also compared. The
subanalysis for response (CR + CRp) was performed in
the same subgroups, using 2-sided Fisher’s exact test
(same method used for the study’s secondary responder
analysis) [8].Allocated to decitabine       (n=242) 
   Received decitabine       (n=238)
   Did not receive decitabine     (n=4) 
Assessed for e
Randomiz
Lost to follow-up        (n=1) 
Discontinued decitabine       (n=211) 
Progressive disease      (n=96) 
Adverse experience      (n=19) 
Patient decision       (n=17) 
Non-compliance      (n=1) 
Death        (n=62) 
Investigator decision      (n=9) 
Other        (n=7) 
Analyzed for efficacy                        (n=242) 
Analyzed for safety                           (n=238) 
Excluded from analysis       (n=4) 
Figure 1 Flow diagram for phase 3 study. Reprinted with permission froThe phase 3 study was registered with ClinicalTrials.
gov with identifier NCT00260832.
Results
Patients
Between January 2006 and April 2009, 485 patients were
randomized at 65 sites. The efficacy population com-
prised 242 decitabine recipients and 243 TC recipients
(cytarabine, n = 215; SC, n = 28; Figure 1). Baseline clin-
ical characteristics and patient demographics were simi-
lar between treatment groups (Table 1) and reflected a
high-risk population [8]. Approximately 71% of patients
were aged ≥70 years, with secondary AML in 35.3%,
poor cytogenetic risk AML in 36.0%, and ECOG PS of 2
in 25.8% of patients; median baseline bone marrow
blasts were 46.0%.Allocated to treatment choice      (n=243) 
   Received treatment choice      (n=237)




Analyzed for efficacy  (n=243) 
Analyzed for safety  (n=237) 
Excluded from safety analysis                                         (n=6) 
Lost to follow-up      (n=1) 
Discontinued treatment choice     (n=228) 
Progressive disease     (n=116) 
Adverse experience     (n=26) 
Patient decision      (n=15) 
Non-compliance     (n=3) 
Death       (n=43) 
Investigator decision     (n=15) 
Other       (n=10) 
m Kantarjian H, et al. J Clin Oncol 2012 [8].






Median age, years (range) 73.0 (64.0–91.0) 73.0 (64.0–89.0)
<70 years 70 (28.8) 71 (29.3)
70–74 years 74 (30.5) 76 (31.4)
≥75 years 99 (40.8) 95 (39.3)
Sex, n (%)
Female 92 (37.9) 105 (43.4)
Male 151 (62.1) 137 (56.6)
Median BSA, m2 (range) 1.80 (1.3–2.7) 1.82 (1.4–2.6)
Median time since AML diagnosis,
days (range)
15.0 (0–398.0) 14.0 (3.0–346.0)
Type of AML, n (%)
De novo 157 (64.6) 155 (64.0)
Secondary 84 (34.6) 87 (36.0)
Bone marrow blasts, n (%)
<20% 8 (3.3) 4 (1.7)
20%–30% 58 (24.1) 65 (27.0)
>30%–50% 74 (30.7) 67 (27.8)
>50% 101 (41.9) 105 (43.7)
ECOG PS, n (%)
0 or 1 178 (73.2) 182 (75.3)
2 65 (26.7) 60 (24.8)
Cytogenetics, n (%)
Intermediate risk 154 (63.6) 152 (63.1)
Poor risk 87 (36.0) 87 (36.1)
Median hemoglobin, g/dL (range) 9.4 (5.0–12.6) 9.3 (5.2–15.0)
Platelets, n 213 225
Median, 109/L (range) 50.00 (6.0–490.0) 58.00 (6.0–487.0)
White blood cells, n 236 237
Median, 109/L (range) 3.69 (0.5–80.9) 3.10 (0.3–127.0)
AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group
Performance Status; TC, treatment choice, with physician’s advice.
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the largest proportion of patients in each treatment group
was from Eastern Europe (46.5%, TC; 45.0%, decitabine).Multivariate analysis
After adjustment for potential prognostic factors, the
HR for treatment effect on OS based on mature data
was 0.799 (95% CI: 0.653–0.978), favoring decitabine
(Table 3). Patient characteristics appearing to negatively
influence OS at the 0.05 level included advanced age,
poorer baseline ECOG PS, poor cytogenetic risk, higher
bone marrow blast counts, low baseline platelet counts,
and higher WBC counts. Geographically, being in theWestern European subgroup was predictive of a longer
median OS.
After adjustment for the same set of potentially prog-
nostic factors in the logistic regression analysis for re-
sponse (CR + CRp), an advantage was noted for
decitabine over TC in response rate (odds ratio [OR]
2.751 [95% CI: 1.487–5.091; p = 0.001). The only patient
characteristic significantly influencing response rate was
sex (male vs female, OR 0.551 [95% CI: 0.304–0.998];
p = 0.049).
Subgroup analyses
Prespecified analyses of subgroups were performed for
OS and response (CR + CRp) using 2010 mature data. In
general, OS results were consistent with those using
2009 data [8], favoring treatment with decitabine with 3
exceptions. In the mature data set, the treatment effect
on OS in the Western European subgroup favored TC,
which was markedly different from the treatment effect
seen in the overall population, which favored decitabine.
Similarly, in the subgroup of patients with baseline bone
marrow blasts of 20% to 30%, the treatment effect on
OS favored TC, but favored decitabine in the overall
population. Finally, for patients aged <70 years, HR was
close to unity, with neither treatment favored. Overall
survival data for these subsets were reported in detail
elsewhere [8].
In the analysis of response rates, all subgroups favored
decitabine (Figure 2).
Age
In patients aged <70 years, a slightly higher proportion
of patients received subsequent treatment (ie, after the
trial ended) with induction chemotherapy in the TC arm
(21.4%) than in the decitabine arm (16.9%), and 7.1% of
patients received a subsequent hypomethylating agent in
the TC arm compared with no patients in the decitabine
arm. In patients aged ≥70 years, a smaller proportion of
patients received subsequent induction chemotherapy
(6.9%, TC arm; 8.2%, decitabine arm), while 9.8% of pa-
tients in the TC arm and 2.3% in the decitabine arm
subsequently received a hypomethylating agent. When
analysis of OS in the age subgroups was censored for
subsequent disease-modifying therapy, an HR favoring
decitabine was observed for all age groups (HR = 0.73,
age ≥75 years; HR = 0.80, age 70–74 years; and HR =
0.97, age <70 years).
Type of acute myeloid leukemia
Although AML type was not a stratification factor, the
numbers of patients with de novo or secondary AML
were well balanced across treatment arms, with approxi-
mately two thirds of patients having de novo AML. Re-
sponse to decitabine was observed in both subgroups





Patients, n (%) Patients, n (%)
Eastern Europe 113 (46.5) 109 (45.0)
Poland 47 (19.3) 41 (16.9)
Russian Federation 29 (11.9) 28 (11.6)
Czech Republic 23 (9.5) 24 (9.9)
Serbia 10 (4.1) 12 (5.0)
Hungary 3 (1.2) 4 (1.7)
Romania 1 (0.4) 0 (0.0)
North America/
Australia
69 (28.4) 51 (21.1)
United States 27 (11.1) 21 (8.7)
Australia 22 (9.1) 16 (6.6)
Canada 20 (8.2) 14 (5.8)
Western Europe 34 (14.0) 51 (21.1)
France 24 (9.9) 31 (12.8)
Spain 10 (4.1) 20 (8.3)
Asia 27 (11.1) 31 (12.8)
Taiwan 27 (11.1) 31 (12.8)
Percentages were calculated using the number of patients in each group as
the denominator.
SC, supportive care; TC, patient's choice of treatment with physician's advice.




95% CI P value
Treatment: decitabine vs TC 0.799 (0.653–0.978) 0.0296
Sex: male vs female 1.125 (0.912–1.388) 0.2703
Age group
70–74 vs <70 years 1.311 (1.004–1.711) 0.0468




Type of AML: de novo vs
secondary
1.110 (0.893–1.380) 0.3452
Baseline ECOG PS: 0 or 1 vs 2 0.771 (0.607–0.978) 0.0321
Geographic region [8]
Eastern Europe vs North
America/Australia
1.118 (0.849–1.473) 0.4263
Western Europe vs North
America/Australia
0.727 (0.523–1.010) 0.0572
Asia vs North America/Australia 1.047 (0.728–1.505) 0.8052
Western Europe vs Eastern Europe 0.650 (0.482–0.877) 0.0048
Western Europe vs Asia 0.694 (0.472–1.021) 0.0637
Baseline bone marrow blast:
>50% vs ≤50%
1.355 (1.099–1.672) 0.0045
Baseline platelets (109/L)a 0.775 (0.663–0.907) 0.0015
Baseline WBC (109/L)b 1.256 (1.045–1.509) 0.0151
AML, acute myeloid leukemia; CI, confidence interval; ECOG PS, Eastern
Cooperative Oncology Group Performance Status; TC, patient's choice of
treatment with physician's advice; WBC, white blood cell counts.
aHazard ratio less than 1 indicates lower risk associated with each additional
100 × 109/L in baseline platelet counts.
bHazard ratio greater than 1 indicates higher risk associated with each
additional 25 × 109/L in baseline WBC counts.
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the larger de novo subgroup.
Baseline bone marrow count
Randomization was not stratified according to baseline
bone marrow blast count, but counts were balanced be-
tween treatment arms: most patients (72%) had a blast
count >30%, while 43% had a blast count >50%. Median
blasts were 45.0% (range: 0–100) in the TC arm and 46.6%
(range: 3–100) in the decitabine arm. For the subgroup of
patients with 20% to 30% blasts, a lower proportion of pa-
tients had an ECOG PS of 0 in the decitabine arm com-
pared with the TC arm (20% vs 31%, respectively), and a
higher percentage of patients in the decitabine arm com-
pared with the TC arm had poor-risk cytogenetics (40.0%
vs 34.5%, respectively) and secondary AML (44.6% vs
39.7%, respectively). The response to decitabine was
clearly demonstrated in patients with baseline bone mar-
row blasts >30% (Figure 2). The small subgroup of pa-
tients with 20% to 30% blasts (n = 65) demonstrated a
significantly better response rate, although notable im-
provements were not observed in OS [8].
Baseline cytogenetic risk
Approximately two thirds of patients had intermediate-risk
cytogenetics at baseline, including those with a normal
karyotype. A trend toward an OS benefit with decitabinetreatment was observed in this subgroup [8]. As expected,
the subgroup of patients with baseline poor-risk cytogenet-
ics had a shorter median OS [8] and somewhat lower re-
sponse rates than those in the group with intermediate-risk
cytogenetics (Figure 2).
Baseline ECOG performance score
Randomization was stratified for ECOG PS; approximately
74.3% of patients had ECOG PS of 0 or 1. As expected, pa-
tients with ECOG PS of 2 showed shorter median OS by
treatment arm versus patients with ECOG PS of 0 or 1 [8].
Also as expected, response rates were greater in patients
with ECOG PS of 0 or 1 (Figure 2). Nevertheless, the sub-
group of patients with ECOG PS of 2 showed an OS bene-
fit with decitabine treatment (HR = 0.65; p = 0.025).
Geographic region
No stratification for geographic region was considered at
randomization, thus some imbalance was noted in the
number of patients in each treatment arm in some regions.
Favoring Decitabine
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Figure 2 Subanalyses of patients with response to either decitabine or treatment choice (complete remission or complete remission
with incomplete platelet recovery). P values were based on 2-sided Fisher’s exact test and stratified by age, cytogenetic risk, and Eastern
Cooperative Oncology Group Performance Status. AML, acute myeloid leukemia; Aus., Australia; CI, confidence interval; ECOG, Eastern Cooperative
Oncology Group; HR, hazard ratio; Med, median (months); NE, not estimable; OR, odds ratio; Resp, responder; TC, patient’s choice of treatment
with physician’s advice.
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patients in the decitabine arm (n = 51) versus the TC arm
(n = 34), and the North American/Australian subgroup had
fewer patients in the decitabine arm (n = 51) than in the
TC arm (n = 69). In the Western European subgroup, OS
appeared to differ markedly from the findings in the pri-
mary study [8] (Figure 3).
Patients from the Western European region in both
the decitabine and TC arms received more cycles of
therapy than did patients in the other regions. In West-
ern European patients in the TC arm, fewer patients had
ECOG PS of 2, poor-risk cytogenetics, or baseline bone
marrow count >50% compared with patients in the deci-
tabine arm. Additionally, more patients in the decitabine
arm were aged >75 years and had poor-risk cytogenetics,
baseline bone marrow blast count >50%, or secondary
AML. Unlike other regions, the Western European re-
gion showed a markedly increased use of subsequent
hypomethylating agents in the TC versus decitabine arm:more than one third of patients (n = 12 [35%]) in the TC
arm subsequently received treatment with a hypomethy-
lating agent, while only 4 patients (8%) in the decitabine
arm were retreated with a hypomethylating agent (in-
cluding decitabine).
Discussion
Decitabine therapy was previously associated with im-
proved (but nonsignificant) outcomes compared with TC
(cytarabine or SC) in older patients with AML [8]. This
multivariate analysis of data from a large, randomized
phase 3 trial in older patients with newly diagnosed
AML demonstrated that all subgroups (age, type of
AML, bone marrow blasts, cytogenetic risk, and ECOG
PS) had responses favoring decitabine, even those with
poorer prognostic factors, such as baseline bone marrow
blasts >30%. Moreover, consistent with known prognos-
tic factors for older patients with AML [10,11], patients
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Figure 3 Overall survival by treatment arm and by geographic region (2010 mature analysis data set). (A) Decitabine arm; (B) Treatment
choice [TC] arm.
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baseline ECOG PS and disease-related factors, such as
poor cytogenetics, higher bone marrow blast counts, low
baseline platelet counts, and high WBC counts, all pre-
dicted worse OS. Interestingly, neither the type of AML
nor patient sex influenced OS.
Despite the association between age and poorer prog-
nosis replicated in these post hoc analyses, the overall
trend for treatment benefit with decitabine was more
clearly observed in patients aged 70–74 years and in pa-
tients ≥75 years compared with those <70 years. Hazard
ratios for OS were 0.79 (p = 0.165) and 0.72 (p = 0.035)
for patients aged 70–74 and ≥75 years, respectively [8].
Patients aged <70 years demonstrated response rates of
16.9% and median OS of 9.1 months [8], which were con-
sistent with overall results for decitabine-treated patients.
Survival and response results in older patients re-
ported in this trial are particularly promising given that
published data indicate that response and survival in
clinical trials are typically diminished as the patient’s age
increases. Median survival in this trial was 8.0 months in
patients aged 70–74 years and 6.3 months in those aged
≥75 years [8], which compares favorably with historical
data in this older population. These favorable findings
for decitabine in older patients are intriguing and may
warrant further investigation to determine the under-
lying explanation. A retrospective analysis of 968 adults
with AML in 5 Southwest Oncology Group trials re-
vealed a median OS of 6.9 months (95% CI: 5.4–7.7) in
patients aged 66–75 years, but only 3.5 months (95% CI:1.4–6.1) in patients older than 75 years [12]. In a separ-
ate analysis of 998 patients aged ≥65 years with AML or
high-risk MDS treated with intensive chemotherapy, me-
dian OS in patients aged 75 and older was only 18 weeks
compared with 34 weeks in patients aged 70–74 years,
and 29 weeks in patients aged 65–69 years [13]. In con-
trast, more recent analyses of azacitidine (n = 55) in
patients with 20% to 30% bone marrow blasts versus
conventional care (best SC, low-dose cytarabine, or
intensive chemotherapy; n = 58) [14], suggest a survival
advantage for azacitidine over conventional care of
24.5 months versus 16.0 months (p = 0.005), respectively,
although the atypically high median OS associated with
conventional care suggests some patient selection bias.
In particular, patients in the azacitidine trial had better
prognostic factors than did the high-risk patients in the
present decitabine trial.
Notable in the current analyses is the outcome for pa-
tients in the Western European subgroup, who had a
longer median OS compared with patients from other
regions. In this small subgroup (n = 85), median OS in
the TC arm (12.5 months) for the primary analysis was
much longer than that in any other region and was associ-
ated with a wide confidence interval. In Western Europe,
fewer patients were randomized to the TC arm than to
the decitabine arm, which contributed to the greater
variability observed in OS curves for the TC arm and to
the wide confidence intervals for HRs. In addition,
fewer patients in the TC arm had factors associated with
poor prognosis compared with those in the decitabine
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quent therapy with hypomethylating agents, as more
patients in the TC arm than in the decitabine arm re-
ceived subsequent disease-modifying therapy with a
hypomethylating agent. Thus, the OS trend seen in this
subgroup might be explained by the combination of the
imbalance in baseline characteristics, the high rate of
subsequent disease-modifying therapy, and the greater
variability of the data owing to the small sample size.
This trial and subsequent analyses had some limitations.
To enable a comparison of an IV regimen of decitabine
with the standard subcutaneous cytarabine regimen, the
trial utilized an open-label study design. Also, sample sizes
were small in some subgroups. Nevertheless, decitabine
demonstrated robust and fairly consistent results across
most defined subgroups in this older population with
AML, with a magnitude of effect consistent with that seen
in other clinical trials of decitabine, such as the phase 2
trial reported by Cashen and colleagues (median OS,
7.7 months) [7]. The underlying reasons why some sub-
groups with typically poor prognoses had favorable re-
sponses to decitabine are not well understood; further
investigation may be warranted to determine the explana-
tions for these findings. The reliability of the results may
lend them validity, despite the trial limitations.
Conclusions
Older patients with AML have characteristics that may
adversely affect response to conventional therapy. In this
multivariate analysis, response to decitabine was associ-
ated with known prognostic factors, such as age, ECOG
PS, and cytogenetics. Subgroup analyses revealed that re-
sponse to decitabine compared with that of cytarabine
or standard care was most clearly demonstrated in pa-
tients aged ≥75 years, a population that is traditionally
difficult to treat, with a poor prognosis.
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